期刊文献+

促红细胞生成素对急性心肌缺血再灌注后大鼠心肌凋亡基因表达影响的实验研究 被引量:4

下载PDF
导出
摘要 目的观察促红细胞生成素(EPO)对急性心肌缺血再灌注心肌凋亡基因表达的影响,探讨EPO的心脏保护机制。方法建立大鼠心肌缺血再灌注模型36只大鼠随机分为假手术组(Sham组)、缺血再灌注对照组(IR组)和EPO组(EPO 3 000 U·kg-1·d-1,共3 d),每组12只。3组48 h、2周缺血边缘区心肌组织Bcl-2、Bax蛋白及血管内皮生长因子(VEGF)蛋白表达(免疫组化法),以及相关基因mRNA的变化(RT-PCR法)。结果与IR组比较,EPO组Bcl-2蛋白表达在48 h、2周、分别增高27.7%、31.4%(P<0.01);Bax蛋白表达在48 h、2周均降低,分别降低20.9%、18.0%(P<0.01);Bcl-2/Bax比值在各时间点均显著增高(P<0.05);EPO组VEGF蛋白表达在48 h、2周均增高,分别增高22.1%、21.4%(P<0.05或<0.01)。与IR组比较,EPO组Bcl-2/BaxmRNA比值在各时间点均显著增高(P<0.05)。结论 EPO可能通过调节Bcl-2、Bax的表达而减少细胞凋亡,抑制缺血而灌注损伤,产生对心脏的保护作用。
出处 《河北医药》 CAS 2014年第19期2913-2915,共3页 Hebei Medical Journal
  • 相关文献

参考文献8

  • 1刘焱,张文亮,李增新.氯沙坦和螺内酯及联合应用对心肌梗死大鼠早期新生血管的影响[J].河北医药,2011,33(10):1455-1457. 被引量:2
  • 2Dong S, Cheng Y, Yang J, et al. MicroRNA Expression Signature and the Rolerof MicroRNA-21 in the Early Phase of Acute Myocardial Infarction. J Biol chem,2009 ,284 :29514-29525.
  • 3Patel NS, Sharpies EJ, Cuzzocrrea S, et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusiou in the mouse kidney in vivo. Kidney Int,2004 ,66 :983-989.
  • 4Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin pretects the myocardium from ischemia-reperfusion injury and promotes beneficial renmodeling. Proc Natl Acad Sci USA ,2003,100:4802-4806.
  • 5Danial NN, Korsmeyer SJ. Cell death: Critical control points. C cell, 2004,116:205-219.
  • 6Vincenti Y, Cassano C, Rocchi M, et al. Assignment of the vascuar endo- thelial growth factor gene to human chromosome 6p21.3. Circulation, 1996,93 : 1493-1495.
  • 7Yockman JW, Choi D, Whitten MG, et al. Polymeric gene delivery of is- chemia-inducible VEGF significantly attenuates infarct size and apoptosis following myocardial infarct. Gene Therapy,2009,16 : 127-135.
  • 8Ruixing Y, Jiaquan L, JIE C, et al. Intravenous administration of vascular endothelial growth factor improves caediac performance and inhibits car- diomvoevte aooptosis. Growth Factors ,2006,24:209-217.

二级参考文献7

  • 1Zannad F, Alia F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone thera- py in patients with congestive heart failure : insights from the randomized aldaetone evaluation study (RALES). Rales Investigators. Circulation, 2000.102:2700-2706.
  • 2Pitt B, Ruilope L, Bakris G, et al. Risk/benefit analysis of hyperkalemia in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Eur J Heart Fail Suppl,2004,3 : 116.
  • 3Shyam Bhakta and Mark E Dunlap. Angiotensin-receptor blockers in heart failure :evidence from the CHARM trial. Cleveland Clinic Journal of Medicine,2004,71 : 665 -673.
  • 4Henry K, Peter C, Csaba F, et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure:results from Val-He FT. Eur J Heart Fail,2004,6:937-945.
  • 5Michel F, Ambroisine ML, Dufiez M, et al. Aldosterone Enhances Ischemia-Induced Neovasculafization Through Angiotensin ]I -Dependent Pathway. Circulation ,2004, 109 : 1933-1937.
  • 6Hayashi M ,Tsutamoto T, Wada A, et al. Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction : extracting aldostcrone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coil Cardiol,2001,38 :1375-1382.
  • 7Munk VC, Miguel LS, Petrimpol M, et al. Angiotensin II Induces Anglogenesis in the Hypoxic Adult Mouse Heart In Vitro Through an AT2-B2 Receptor Pathway. Hypertension ,2007,49 : 1178-1185.

共引文献1

同被引文献54

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部